Omeros Corporation's SEC filings document the regulatory record of a commercial-stage biotechnology company focused on protein and small-molecule therapeutics, including YARTEMLEA, OMS1029 and programs in complement-mediated diseases, cancers, and addictive or compulsive disorders. Form 8-K reports cover operating and financial results, material-event disclosures, clinical and regulatory updates, material agreements, and capital-structure matters.
Proxy materials describe annual shareholder meeting mechanics, director elections, executive-compensation votes, board governance and related shareholder voting matters. The filing record also includes formal disclosure of the FDA approval of YARTEMLEA for TA-TMA and financial-condition information tied to Omeros' commercialization and development-stage pipeline.
Omeros Corporation (OMER) – Form 4 filing dated 07/01/2025
Non-employee director Dr. Peter A. Demopulos was automatically granted a stock option for 15,000 common shares under the company’s director compensation policy following the annual shareholder meeting on 06/27/2025. The option’s key terms are:
- Exercise price: $3.20 per share
- Expiration: 06/27/2035 (10-year tenor)
- Vesting: fully vests the day before the 2026 annual meeting, contingent on continued board service
- Ownership designation: direct (D); post-grant derivative holdings reported at 15,000 options
The filing reflects routine annual equity compensation for board members and does not disclose any open-market purchases or sales of common shares.
On June 27, 2025, Omeros Corporation (ticker: OMER) granted non-employee director Thomas F. Bumol a stock option for 15,000 common shares at an exercise price of $3.20 per share, as disclosed in this Form 4 filed on July 1, 2025. The award is part of the company’s recurring director compensation program, automatically issued at each annual shareholder meeting to directors who have served at least six months and will continue to serve. The option vests in full on the day prior to the 2026 annual meeting, contingent upon Bumol’s continued board service. Following the grant, Bumol beneficially owns 15,000 derivative securities (options) with direct ownership. No shares of common stock were bought or sold, and no cash consideration changed hands.
The filing is a standard, non-cash compensation event and does not involve open-market transactions, changes in beneficial ownership of outstanding common shares, or the adoption of a Rule 10b5-1 trading plan. As such, it is considered routine in nature and is unlikely to have a material impact on Omeros’s valuation or trading dynamics.